Abstract 1540P
Background
Neoadjuvant chemoradiotherapy (nCRT) is a standard treatment for resectable locally advanced oesophageal squamous cell carcinoma (ESCC); however, its effectiveness is curtailed by recurrence and distant metastasis. Developing novel therapies, such as combined checkpoint inhibitors, is crucial for improving patient survival. Tislelizumab, an anti-PD-1 monoclonal antibody, has shown promise in various malignancies. This is the first phase II study to assess the efficacy and safety of Tislelizumab combined with nCRT for resectable locally advanced ESCC.
Methods
All subjects underwent nCRT with a 40 Gy total radiation dose given daily for 5 days/week. Paclitaxel albumin (taxanes) with cisplatin/carboplatin were given on days 1 and 22, while Tislelizumab was administered twice on days 8 and 29 concurrently with radiation therapy. Finally, surgery was performed at 6-8 weeks post-treatment.
Results
By April 2023, 26 patients were enrolled in the study, with 21 undergoing surgical resection at a 100% R0 resection rate. Patients who received Tislelizumab combined with nCRT achieved a 100% objective remission rate, with 9 (42.8%) patients had complete response rate and 14 (66.6%) patients achieved major pathologic response, no surgical delay, among 6 patients continue to receive postoperative adjuvant therapy. Common side-effects included leukopenia, thrombocytopenia, neutropenia, anemia, anastomotic leakage, and rash. Most adverse events were grades 1/2, and grades 3/4 adverse events include four cases of grade 3 leukopenia, and one case of grade 3 neutropenia. Regrettably, 2 patients have passed away due to the novel coronavirus. The analysis of survival was immature, and patients are still being followed up.
Conclusions
Tislelizumab in combination with nCRT is a safe and effective treatment strategy for resectable locally advanced ESCC. The high complete response rate and favorable safety profile observed in this study warrant further investigation in larger, randomized controlled trials to confirm the benefit of Tislelizumab in improving treatment outcomes for patients with locally advanced ESCC.
Clinical trial identification
CTR2100051599.
Editorial acknowledgement
The drug was kindly provided by Beigene and Kelun.
Legal entity responsible for the study
The authors.
Funding
Clinical Research Incubation Project, West China Hospital, Sichuan University; Science and Technology Department of Sichuan Province; Beijing Medical Award Foundation; the 1·3·5 project for disciplines of excellence; National Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1532P - Phase Ib study of futibatinib plus pembrolizumab in patients with esophageal carcinoma: Updated results of antitumor activity and tolerability results in combination with chemotherapy
Presenter: Shun Yamamoto
Session: Poster session 21
1535P - Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO
Presenter: Magdalena Scheck
Session: Poster session 21
1536P - HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+ advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome
Presenter: Joshua Tobias
Session: Poster session 21
1537P - A phase I study of pevonedistat plus capeOX in patients with advanced gastric cancer refractory to platinum (NCCH-1811)
Presenter: Daisuke Takahari
Session: Poster session 21
1541P - Neoadjuvant therapy of camrelizumab combined with chemotherapy in patients (pts) with resectable esophageal squamous cell cancer (ESCC)
Presenter: Yinjun Dong
Session: Poster session 21
1542P - Updated results of a phase II clinical trial: Paclitaxel and carboplatin plus PD-1 blockades combined with anlotinib as first-line treatment for advanced oesophageal cancer
Presenter: Mingfang Xu
Session: Poster session 21